BIOMARIN PHARMACEUTICAL INC Interest Expense Nonoperating
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Interest Expense Nonoperating of $63.30 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for the quarter ending 2026-06-30 was $63.30M, a 2262.64% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for the quarter ending 2026-03-31 was $14.96M, a 422.46% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for the quarter ending 2025-12-31 was $2.78M, a 7.80% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for the quarter ending 2025-09-30 was $2.58M, a 13.11% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for fiscal 2025 was $10.90M, a 13.95% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for fiscal 2024 was $12.67M, a 26.93% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for fiscal 2023 was $17.34M, a 8.55% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC interest expense nonoperating for fiscal 2022 was $15.97M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $63.30M 10-Q · filed 2026-08-06 | $78.25M 10-Q · filed 2026-08-06 | $81.03M derived: sum of 3 quarters · filed 2026-08-06 | $83.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $14.96M 10-Q · filed 2026-05-05 | $17.74M derived: sum of 2 quarters · filed 2026-05-05 | $20.32M derived: sum of 3 quarters · filed 2026-05-05 | $22.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.36M derived: sum of 2 quarters · filed 2026-02-26 | $8.04M derived: sum of 3 quarters · filed 2026-08-06 | $10.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.58M 10-Q · filed 2025-10-28 | $5.26M derived: sum of 2 quarters · filed 2026-08-06 | $8.12M 10-Q · filed 2025-10-28 | $10.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.68M 10-Q · filed 2026-08-06 | $5.54M 10-Q · filed 2026-08-06 | $8.12M derived: sum of 3 quarters · filed 2026-08-06 | $11.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.86M 10-Q · filed 2026-05-05 | $5.44M derived: sum of 2 quarters · filed 2026-05-05 | $8.41M derived: sum of 3 quarters · filed 2026-05-05 | $11.98M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.54M derived: sum of 2 quarters · filed 2026-02-26 | $9.12M derived: sum of 3 quarters · filed 2026-02-26 | $12.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.97M 10-Q · filed 2025-10-28 | $6.54M derived: sum of 2 quarters · filed 2025-10-28 | $10.09M 10-Q · filed 2025-10-28 | $16.19M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.57M 10-Q · filed 2025-08-05 | $7.12M 10-Q · filed 2025-08-05 | $13.22M derived: sum of 3 quarters · filed 2026-02-26 | $17.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.55M 10-Q · filed 2025-05-02 | $9.64M derived: sum of 2 quarters · filed 2026-02-26 | $13.42M derived: sum of 3 quarters · filed 2026-02-26 | $17.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $9.88M derived: sum of 2 quarters · filed 2026-02-26 | $13.63M derived: sum of 3 quarters · filed 2026-02-26 | $17.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.78M 10-Q · filed 2024-10-31 | $7.53M derived: sum of 2 quarters · filed 2024-10-31 | $11.24M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $3.75M 10-Q · filed 2024-08-05 | $7.46M 10-Q · filed 2024-08-05 | ||
| 2022-12-31 | $15.97M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |